First, we investigated the effects of BRAF and/or MEK inhibition (using dabrafenib and trametinib, respectively) on MAPK pathway activation in KRAS-mut lung and pancreatic cancer cell lines (Additional file 1: Table S1). The gene discussed is BRAF; the disease is familial pancreatic carcinoma.